Small orphan drug firms caught by Germany's AMNOG assessments
This article was originally published in Scrip
Executive Summary
Small companies with orphan drug products whose turnover is less than €50 million are not excluded from cost-effectiveness assessments introduced this year under Germany’s healthcare reform act, said Dr Alexander Natz, Brussels representative for the BPI, the German association for mid-sized pharma companies. In an interview with Scrip, he warned companies not to be complacent